Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid

Ellagic acid (EA) is a naturally occurring polyphenolic compound endowed with strong antioxidant and anticancer properties that is present in high quantity in a variety of berries, pomegranates, and dried fruits. The antitumor activity of EA has been mostly attributed to direct antiproliferative and...

Full description

Saved in:
Bibliographic Details
Published in:Nutrients 2018-11, Vol.10 (11), p.1756
Main Authors: Ceci, Claudia, Lacal, Pedro M, Tentori, Lucio, De Martino, Maria Gabriella, Miano, Roberto, Graziani, Grazia
Format: Article
Language:English
Subjects:
angiogenesis
Angiogenesis Inhibitors - chemistry
Angiogenesis Inhibitors - pharmacology
Animals
Antineoplastic Agents, Phytogenic - chemistry
Antineoplastic Agents, Phytogenic - pharmacology
bladder cancer
breast cancer
colorectal cancer
Ellagic Acid - chemistry
Ellagic Acid - pharmacology
melanoma
metastases
non-small cell lung cancer (NSCLC)
ovarian cancer
polyphenolic compounds
prostate cancer
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ellagic acid (EA) is a naturally occurring polyphenolic compound endowed with strong antioxidant and anticancer properties that is present in high quantity in a variety of berries, pomegranates, and dried fruits. The antitumor activity of EA has been mostly attributed to direct antiproliferative and apoptotic effects. Moreover, EA can inhibit tumour cell migration, extra-cellular matrix invasion and angiogenesis, all processes that are crucial for tumour infiltrative behaviour and the metastatic process. In addition, EA may increase tumour sensitivity to chemotherapy and radiotherapy. The aim of this review is to summarize the in vitro and in vivo experimental evidence supporting the anticancer activity of pure EA, its metabolites, and EA-containing fruit juice or extracts in a variety of solid tumour models. The EA oral administration as supportive therapy to standard chemotherapy has been recently evaluated in small clinical studies with colorectal or prostate cancer patients. Novel formulations with improved solubility and bioavailability are expected to fully develop the therapeutic potential of EA derivatives in the near future.
ISSN:2072-6643
2072-6643
DOI:10.3390/nu10111756